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ABSTRACT
A total of 1276 dogs of various breeds and both sexes were presented to the Teaching Veterinary Clinical 
Complex, Bhoiguda, College of Veterinary Science, Hyderabad with a history and signs of cardio-pulmonary 
disorders, from 2004 to 2008. Based on physical, electrocardiographic, radiographic and echocardiographic 
examinations, 12 dogs were diagnosed with Hypertrophic Cardiomyopathy (HCM). No abnormalities were 
detected from the Complete Blood Count and blood biochemistry, except elevated levels of Creatine Kinase MB 
and Lactate Dehydrogenase. All the HCM dogs revealed common manifestations such as: exercise intolerance, 
poor appetite, lethargy, cough, seizures (8 dogs) and syncope (6 dogs) for more than a couple of weeks. The 
HCM dogs were under treatment for more than a month with diuretics and Angiotensin Converting Enzyme 
(ACE)-inhibitors but without any improvement. After supplementation of diltiazem along with ramipril and 
frusemide, improvement in clinical manifestations were noticed over 3-5 days and complete clinical recovery 
after 30-60 days. Hence, from the present fi ndings it may be concluded that echocardiography is the most 
sensitive mode of diagnosis and the role of diltiazem in successful treatment of HCM in dogs is clear.
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Introduction 
Hypertrophic cardiomyopathy (HCM) is pragmatically defi ned as inappropriate 
myocardial hypertrophy of a non-dilated left ventricle, occurring in the absence of an 
identifi able stimulus for the hypertrophy (WYNNE and BRAUNWALD, 1997). HCM 
typically affects middle aged cats is relatively uncommon in dogs. Most are affected with 
murmurs or gallop and signifi cantly with heart failure (MARKS, 1993). The majority of 
identifi ed dogs have been males, of younger age (less than 5 yrs) and the condition was 
reported to be inherited in pointers (SISSON, 1990). Though some scattered information 
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is available in literature published abroad on HCM dogs, there is a dearth in India. The 
present paper is the fi rst of its kind in India to record retrospectively the manifestations, 
diagnosis and therapeutic management of hypertrophic cardiomyopathy in dogs.
Materials and methods
The present investigation was carried out at the Teaching Veterinary Clinical Complex 
(TVCC), Bhoiguda, College of Veterinary Science, Hyderabad, Andhra Pradesh, India 
over a period of 4 years (2004-2008). Out of a total of 1276 dogs of various breeds, ages 
and both sexes presented to the Cardiology ward with symptoms suggestive of cardio-
pulmonary disease, on the basis of echocardiographic fi ndings 12 dogs were diagnosed 
for HCM. At the time of presentation all the HCM dogs had been clinically evaluated at 
various hospitals and had been under conventional therapy for heart failure (enalapril 
and frusemide) for a couple of weeks but with no improvement. All the twelve dogs were 
subjected to physical examination. Electrocardiography was performed in right lateral 
recumbancy using a BPL Cardiart 1608 and whereas radiographic evaluation was done 
on left lateral and ventro-dorsal exposures using a Siemens X-ray unit. Further, blood 
was collected for complete blood count, serum biochemical profi le and thyroid profi le. 
The presence of canine heart worm was also tested by heartworm antigen test using Agen 
CHW® kit. Finally, Cardiac ultrasonography was performed using Ixos vet ultrasound / 
Doppler machine supplied by Esoate Pie Medicals, Netherlands. A micro convex Array 
C5-2 R13 cardiac probe was used for echocardiographic studies. All the twelve dogs 
confi rmed for HCM were treated with oral diltiazem at the rate of 1.5 mg/kg, ramipril at 
the rate of 0.5 mg/kg, BID for 15 days followed by SID for 30-60 days and frusemide at 
the rate of 2 mg/kg, SID, PO for 10 days.
Results 
All twelve dogs were presented with similar manifestations such as: exercise 
intolerance, poor appetite, lethargy and cough for more than two weeks. Further, seizures 
(8 dogs), syncope (6 dogs) and both (3 dogs) were also reported when excited. The twelve 
dogs (11 male and 1 female) diagnosed for HCM were aged between 10-13 years and 9 
were Boxers and 3, Doberman pinchers. Physical examination revealed lethargy, ascites 
(3 dogs) with normal temperature, pulse and respiratory rates. Mild systolic murmurs 
were detected on auscultation of the cardiac area on the left side of the thorax between 
the 3rd to 5th intercostal spaces, and mild crackles over lung area.
The mean haematological parameters viz: total erythrocyte count, haemoglobin, total 
leukocyte count and differential count, were well within the normal range. The mean 
creatine kinase MB (89.6 ± 0.72 U/L) and lactate dehydrogenase (144.68 ± 1.24 U/L) 
levels were elevated when compared to the mean levels of healthy dogs (22.26 ± 0.14 U/L 
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and 80.45 ± 0.58 U/L). However, the other serum biochemical parameters (total serum 
proteins, albumin, aspertate amino transferase and cholesterol) were within the normal 
range. No abnormality was detected in the values of T3, T4 and TSH. Further, the test for 
heartworm antigen was also negative.
Fig. 1. Hypertrophied interventricular septum and left ventricle free wall. Also note increased 
fractions (EF & FS).
Fig. 2. Thickened left ventricle free wall and interventricular septum. Also note enlarged left 
atrium.
Electrocardiographic abnormalities include increased R wave amplitude, deep Q wave 
and ST coving. Five of the twelve dogs also revealed wide and bizarre QRS complexes.
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Fig. 3. Muscular ridge on short axis view-a third papillary muscle appearance
Thoracic radiography revealed cardiomegaly and moderate pulmonary edema 
suggestive of left side heart failure. However, abdominal radiograph in 2 ascite dogs 
with pendulous abdomen, revealed a ground glass appearance and loss of overall visceral 
detail, consistent with ascites. Abdominal ultrasonography also revealed an anechoeic 
region in the abdominal cavity, suggestive of fl uid accumulation.
Two-dimensional echocardiography revealed a thickened left ventricular free wall 
and interventricular septum (Fig.1). The left ventricular chambers appeared smaller and 
the left atrial diameter larger than normal (Fig. 2). Functional obstruction to outfl ow was 
not observed during systole; however, pressure gradients across the outfl ow tract were 
not measured. M-mode echocardiography revealed a mean ejection fraction (92%) and 
fractional shortening (86%) that were greater than normal (Fig. 1). Further, a muscular 
ridge of the myocardium was also present in the left ventricle outfl ow tract on a short axis 
view (Fig. 3).
Based on the echocardiographic, radiographic and electrocardiographic fi ndings, 
along with the history of seizures and/or syncope, the condition was diagnosed as 
hypertrophic cardiomyopathy. After the initiation of therapy with diltiazam, ramipril and 
frusemide, clinical improvement was noticed from day 3 (in 8 dogs) and 5 (in 4 dogs). 
The crackles and murmurs that had been auscultated diminished in intensity, coughing 
was less frequent and the amount of ascitic fl uid decreased by day 5 (in 8 dogs) and 7 (in 
4 dogs). Complete alleviation of clinical signs with absence of cough, ascites (2 dogs), 
improvement in physical activity and appetite was observed by day 30 in all the HCM dogs. 
However, the owners were advised to continue diltiazem (1.5 mg/kg, PO) and ramipril 
(0.5 mg/kg, PO). It was reported that all the dogs continued to improve and became 
much brighter and active over the next 30 days. After therapy, no appreciable changes 
in thoracic radiographs were noticed except the absence of pulmonary edema. Similarly 
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apart from the absence of arrhythmias, no differences in ECG and echocardiographic 
features were detected in all the HCM treated dogs, suggestive of clinical recovery. 
Discussion
Primary HCM is characterized by hypertrophy of the left ventricle, a small left 
ventricular cavity and diastolic dysfunction associated with decreased left ventricular 
compliance and increased fi lling pressure. It results in pulmonary edema, dyspnoea, 
inadequate cardiac output, lethargy and sudden death (MARON and EPSTEIN, 1979). 
Although the disease is commonly diagnosed in cats and human beings, it is an 
infrequently identifi ed cause of heart disease in dogs, and the majority of identifi ed dogs 
are males (SISSON et al., 1999). The cause of primary HCM is not known. In dogs, HCM 
is commonly noticed in German Shepherds, Boxers, Rottweilers and Doberman Pinchers 
(SISSON and THOMAS, 1995).
Elevated R wave, ST coving, bizarre QRS complexes observed in the present dogs 
are the common ECG abnormalities associated with HCM in dogs (MARKS, 1993). These 
abnormalities were suggestive of left ventricle enlargement with ventricular conduction 
abnormalities.
When the left ventricle hypertrophies, the anterolateral free wall and the interventricular 
septum are affected; however, the septum is usually more severely affected than the left 
ventricular free wall. A septal-to-free wall thickness ratio >1 suggests the possibility of 
functional outfl ow obstruction (MARON and EPSTEIN, 1979). Septal-free wall thickness 
ratios in 10 dogs ranged from 1.1 to 1.5; in the majority (6 dogs) it was greater than or 
equal to 1.3 (LIU et al., 1979). In the dogs in our study, the septal-to-free wall thickness 
ratio was 1 and subjective assessment with two-dimensional echocardiography suggested 
that there was no obstruction. However, because pressure gradients across the outfl ow 
tract were not measured, non-obstructive HCM could not be confi rmed.
A complete echo and Doppler examination is the best method to evaluate HCM 
and dynamic left ventricular outfl ow tract obstruction (DLVOTO). The most common 
echocardiographic feature of canine HCM is the presence of left ventricular concentric 
hypertrophy. A muscular ridge of myocardium is some times present in the LVOT, that 
can be most easily appreciated on a short axis view where it assumes the presence of an 
accessory papillary muscle (SISSON et al., 1999). Mitral fl ow showing a decreased E peak, 
increased A velocities and deceleration times, indicates impaired ventricular relaxation 
(MARON and EPSTEIN, 1980; MAJO et al., 2003). In the present study, no such mitral valve 
abnormalities were detected on echocardiography.
Thickening of the ventricular walls increases myocardial oxygen demand and the 
distance between capillaries. These multiple structural changes may predispose the 
myocardium to regional ischemia and subsequent scaring (KATA, 1990; LIU et al., 1979).
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One aspect of diastolic dysfunction seen with HCM is incomplete, asynchronous 
relaxation of the heart. This impaired relaxation could be explained, in part, by 
abnormalities in myocardial calcium kinetics that cause an increase in the intracellular 
calcium concentration. An increase in the number of calcium channels, mediating abnormal 
calcium fl uxes, helps by some unknown mechanism to produce hypertrophy and fi bre 
disarray (WYNNE and BRAUNWALD, 1997). Two principle functional disturbances occur 
in patients with HCM: impaired diastolic fi lling and dynamic LVOT obstruction. Altered 
diastolic fi lling is the most pervasive hemodynamic change in human patients, as it is 
abnormal in patients with and without LVOT obstruction (WYNNE and BRAUNWALD, 
1997). Diastolic dysfunction results from impaired relaxation in the early diastolic phase 
and from reduced ventricular compliance. The reduced rate and uniformity of ventricular 
relaxation in early diastole are thought to be caused by abnormal myocardial calcium 
kinetics, which results in increased concentration of intracellular calcium (MARON et al., 
1987). The consequences of diastolic dysfunction include an impaired ability to increase 
cardiac output during stress or exercise, as well as a propensity to develop pulmonary 
congestion and edema due to increased left atrial and pulmonary venous pressures. Any 
increase in the heart rate exacerbates the severity of diastolic dysfunction.
Drugs that enhance ventricular relaxation and slow the heart rate, including the beta 
adrenergic and calcium channel blockers, are indicated in the treatment of the diastolic 
dysfunction of HCM. Beta blockers improve diastolic performance only indirectly, 
enhancing ventricular fi lling by reducing heart rate and improving myocardial perfusion. 
Traditionally, beta-blockers have been administered orally to reduce and prevent 
elevations in left ventricle end diastole pressure, to lower systolic pressure gradients 
and myocardial oxygen requirements, to prevent stress-induced tachycardia and reduce 
resting heart rate and for their anti-arrhythmic effects. When arrhythmias are present, this 
drug may be initiated earlier in the disease course. Calcium channel blocking agents have 
been effective in human HCM by reducing heart rate, myocardial oxygen consumption 
and diastolic dysfunction. In addition to directly enhancing myocardial relaxation, these 
drugs produce strong coronary vasodilatation and a mild peripheral one. Authors have 
demonstrated the utility of diltiazem in the treatment of feline HCM, including those cases 
refractory to the beta blockers (BRIGHT and GOLDEN, 1991). Calcium channel blockers 
have been shown to be effective in the management of HCM. They decrease intracellular 
calcium concentrations, thereby helping to promote relaxation and improve fi lling of the 
heart (BRIGHT et al., 1999). Administration of diltiazem, the calcium channel blocker used 
in the dogs in the present study resulted in a sustained improvement in clinical signs for 
several weeks.
 A reduction in wall thickness was reported with the administration of enalapril to 
cats with HCM (TAUGNER, 2001). This suggests a potential role for ACE-inhibitors in 
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the treatment of HCM, while it is logical that the rennin-angiotensin-aldosterone system 
is not pathologically activated in asymptomatic patients, and hence ACE-inhibitors might 
not be useful in them. These drugs are generally safe and do play a role in symptomatic 
HCM dogs. Angiotensin converting the enzyme inhibitor, ramipril was also added for the 
present symptomatic HCM dogs as the Renin-Aldosterone activation system had been 
triggered and was responsible for the manifestations resulting in HCM. Frusemide, a 
loop diuretic, was also indicated to reduce fl uid overload and resolve pulmonary edema 
in hypertrophic cardiomyopathy dogs (MARKS, 1993). Supplementation of diuretic in 
the present dogs was found effective in resolving abnormal fl uid accumulations in body 
tissues.
Dogs exhibiting the clinical signs of heart failure did not always respond to 
conventional medical therapy for congestive heart failure. A complete cardiac evaluation, 
including echocardiography is essential in determining the exact cause and to initiate 
the correct treatment for heart failure patients. Addition of calcium channel blockers is 
more valuable in treating HCM dogs, as for the dogs in the present report it resulted in 
sustained improvement of clinical signs for several weeks.
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SAŽETAK
Od 2004. do 2008. godine 1276 pasa različitih pasmina i spola s anamnezom i znakovima kardiopulmonalnih 
poremećaja bilo je pretraženo na Klinici Bhoiguda Kolidža veterinarske znanosti Hyderabad u Indiji. Na osnovi 
fi zikalne, elektrokardiografske, radiografske i ehokardiografske pretrage u 12 je pasa bila dijagnosticirana 
hipertrofi čna kardiomiopatija. Pretragom kompletne krvne slike i biokemijskih pokazatelja u njih nisu bili 
ustanovljeni drugi poremećaji osim povišene razine kreatin kinaze MB i laktat dehidrogenaze. Svi psi s 
hipertrofi čnom kardiomiopatijom pokazivali su uobičajene znakove kao što su nevoljko kretanje, slab apetit, 
pospanost, napadaje kašlja (osam pasa) i nesvjestice (6 pasa) tijekom nekoliko tjedana. Psi su bili liječeni 
više od mjesec dana diureticima i inhibitorima enzima konverzije angiotenzina, ali bez ikakva poboljšanja. 
Nakon primjene diltiazema istododobno s ramiprilom i fursemidom zabilježeno je kliničko poboljšanje za 
tri do pet dana, a potpun klinički oporavak za 30 do 60 dana. Iz postignutih rezultata može se zaključiti da 
je ehokardiografi ja najosjetljivija metoda za dijagnosticiranje, a da je diltiazem važan za uspješno liječenje 
hipertrofi čne kardiomiopatije u pasa.
 Ključne riječi: hipertrofi čna kardiomiopatija, pas, diltiazem 
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